Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study

Br J Psychiatry. 2015 Feb;206(2):145-52. doi: 10.1192/bjp.bp.114.148643. Epub 2014 Nov 27.

Abstract

Background: Dementia with Lewy bodies (DLB) is underrecognised in clinical settings.

Aims: To investigate whether performing a (123)I-ioflupane injection ((123)I-FP-CIT also called DaTSCAN™) single photon emission computed tomography (SPECT) scan in patients with possible DLB would lead to a more certain diagnosis (probable DLB or non-DLB dementia).

Method: We randomised 187 patients with possible DLB 2:1 to have a scan or not (control group). The outcome measure was a change in diagnosis to probable DLB or non-DLB.

Results: There were 56 controls and 114 scanned patients, of whom 43% had an abnormal scan. More patients in the imaging group had a change in diagnosis compared with controls at 8 and 24 weeks (61% (n = 70) v. 4% (n = 2) and 71% (n = 77) v. 16% (n = 9); both P<0.0001). Clinicians were more likely to change the diagnosis if the scan was abnormal (82%) than if it was normal (46%).

Conclusions: Imaging significantly contributed to a more certain diagnosis, proving to be a useful adjunct in the work-up of patients with possible DLB.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Brain / metabolism
  • Dopamine Plasma Membrane Transport Proteins / metabolism*
  • Female
  • Humans
  • Lewy Body Disease / diagnostic imaging*
  • Male
  • Nortropanes*
  • Predictive Value of Tests
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • Dopamine Plasma Membrane Transport Proteins
  • Nortropanes
  • ioflupane